View : 167 Download: 0

PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B

Title
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B
Authors
Chun, Ho SooPapatheodoridis, George V.Lee, MinjongLee, Hye AhKim, Yeong HwaOh, Yun-SeoPark, Su JinKim, JihyeLee, Han AhKim, Hwi YoungKim, Tae HunYoon, Eileen L.Jun, Dae WonAhn, Sang HoonSypsa, VanaYurdaydin, CihanLampertico, PietroCalleja, Jose LuisJanssen, Harry L. A.Dalekos, George N.Goulis, JohnBerg, ThomasButi, MariaKim, Seung UpKim, Yoon Jun
Ewha Authors
김태헌김휘영이민종이혜아전호수이한아
SCOPUS Author ID
김태헌scopusscopus; 김휘영scopus; 이민종scopus; 이혜아scopus; 전호수scopus; 이한아scopusscopus
Issue Date
2024
Journal Title
JOURNAL OF HEPATOLOGY
ISSN
0168-8278JCR Link

1600-0641JCR Link
Citation
JOURNAL OF HEPATOLOGY vol. 80, no. 1
Keywords
HBeAg-positive chronic hepatitis BHBeAg-positive chronic infectionhepatocellular carcinomarisk prediction model
Publisher
ELSEVIER
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Background & Aims: Recent studies reported that moderate HBV DNA levels are significantly associated with hepatocellular carcinoma (HCC) risk in hepatitis B e antigen (HBeAg)-positive, non-cirrhotic patients with chronic hepatitis B (CHB). We aimed to develop and validate a new risk score to predict HCC development using baseline moderate HBV DNA levels in patients entering into HBeAg-positive CHB from chronic infection. Methods: This multicenter cohort study recruited 3,585 HBeAg-positive, non-cirrhotic patients who started antiviral treatment with entecavir or tenofovir disoproxil fumarate at phase change into CHB from chronic infection in 23 tertiary university-affiliated hospitals of South Korea (2012-2020). A new HCC risk score (PAGED-B) was developed (training cohort, n = 2,367) based on multivariable Cox models. Internal validation using bootstrap sampling and external validation (validation cohort, n = 1,218) were performed. Results: Sixty (1.7%) patients developed HCC (median follow-up, 5.4 years). In the training cohort, age, gender, platelets, diabetes and moderate HBV DNA levels (5.00-7.99 log10 IU/ml) were independently associated with HCC development; the PAGED-B score (based on these five predictors) showed a time-dependent AUROC of 0.81 for the prediction of HCC development at 5 years. In the validation cohort, the AUROC of PAGED-B was 0.85, significantly higher than for other risk scores (PAGE-B, mPAGE-B, CAMD, and REAL-B). When stratified by the PAGED-B score, the HCC risk was significantly higher in highrisk patients than in low-risk patients (sub-distribution hazard ratio = 8.43 in the training and 11.59 in the validation cohorts, all p <0.001). Conclusions: The newly established PAGED-B score may enable risk stratification for HCC at the time of transition into HBeAgpositive CHB. (c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
DOI
10.1016/j.jhep.2023.09.011|http://dx.doi.org/10.1016/j.jhep.2023.09.011
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE